PsyBio Therapeutics Corp. (PSYBF)
Chart Events
Performance Outlook
| Previous Close | 0.0325 |
| Open | 0.0325 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0325 - 0.0325 |
| 52 Week Range | 0.0120 - 0.1450 |
| Volume | |
| Avg. Volume | 12,216 |
| Market Cap | 4.425M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0860 |
| Earnings Date | Jun 01, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
PsyBio Therapeutics Founder Wins Best Pitch at Investment Summit
Prestigious award recognizes innovative company as a leading player in the emerging field of psychedelic medicine Miami, Florida--(Newsfile Corp. - March 13, 2023) - Evan Levine, CEO and Founder of PsyBio Therapeutics, won Best Pitch at Kahner Global's Cannabis & Psychedelics Investment Summit last week. Levine was awarded for his visionary approach to developing next-generation therapies for mental health conditions using cutting-edge research and development methods.The Summit is an annual con
- Simply Wall St.
A PsyBio Therapeutics Corp. (CVE:PSYB) insider increased their holdings last year
Looking at PsyBio Therapeutics Corp.'s ( CVE:PSYB ) insider transactions over the last year, we can see that insiders...
- Newsfile
PsyBio Announces Closing of Second Tranche of Private Placement
Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - January 13, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the second tranche of its previously announced non-brokered private placement offering of
